Wells Fargo & Company Silence Therapeutics PLC Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
A detailed history of Wells Fargo & Company transactions in Silence Therapeutics PLC stock. As of the latest transaction made, Wells Fargo & Company holds 19 shares of SLN stock, worth $120. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19Holding current value
$120% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SLN
# of Institutions
71Shares Held
28.1MCall Options Held
300Put Options Held
2K-
Tcg Crossover Management, LLC Palo Alto, CA3.03MShares$19.2 Million7.16% of portfolio
-
Siren, L.L.C. New York, NY2.83MShares$18 Million2.57% of portfolio
-
Lombard Odier Asset Management (Usa) Corp New York, NY2.66MShares$16.9 Million3.3% of portfolio
-
Redmile Group, LLC San Francisco, CA1.9MShares$12 Million2.26% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.15MShares$7.28 Million1.12% of portfolio
About Silence Therapeutics plc
- Ticker SLN
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,888,400
- Market Cap $228M
- Description
- Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated...